Dr. Patrick Beusker (Synthon Biopharmaceuticals BV) visited Syncom to present the latest results on novel duocarmycin-based HER2-targeting antibody-drug conjugates (ADC). Antibody-drug conjugates combine the specificity of antibodies directed against tumor-associated targets with potent cytotoxicity. Synthon BV has proprietary ADC technology that comprises highly potent cell-killing drugs and sophisticated linker and (site-specific) conjugation technologies.
Patrick obtained his PhD at the University of Nijmegen under the supervision of Dr. Scheeren and Prof. Dr. Nolte. In 2001 he became Founder and Chief Scientific Officer of Syntarga BV. Syntarga BV, a spin-off company from the University of Nijmegen, focused his activities on antibody-drug conjugate technology and products for anti-tumor therapy. Since 2011, Patrick is Director of Antibody-Drug Conjugates and Director of Medicinal & Protein Chemistry at Synthon Biopharmaceuticals BV (Nijmegen, The Netherlands).